Tagged with US

Pharma Despite the already existing efficiencies in the Italian healthcare system, there is still significant room for improvement. Johnson & Johnson Medical’s head for southern Europe discusses a number of opportunities where the company can help to improve healthcare quality while reducing costs holistically. Given Italy’s current healthcare sustainability concerns, what…

Pharma 3PL player BOMI Group went public via an IPO in June 2015. VP & CFO Marco Ruini discusses the reasons behind this Italian family company’s decision to go public, as well as its ambitious expansion strategy. How would you assess the success of the IPO that took place last year? This IPO…

Pharma Róbert Ésik, President of the Hungarian Investment Promotion Agency (HIPA), shares his insights into what makes Hungary such an attractive destination for foreign direct investment and ways that the agency will work to increase the amount of FDI in the country. He also discusses the unique Hungarian business culture and…

Pharma Veronika Ferencz, Sales and Marketing Director for Exeltis Hungary, discusses the evolving and expanding footprint of the company in Hungary, the challenges strict regulations on food supplements are causing, as well as the need for better recognition of women’s health as a therapeutic area. She also reflects on her own…

Pharma The leadership of Meditop discuss their history as the first non-privatized, private Hungarian pharmaceutical company, their ongoing strategies for growth in the country, and their evolving portfolio abroad. They also discuss the complexities of the Hungarian healthcare and pharmaceutical market and give an overview of their past challenges and current…

Pharma KPMG is committed to providing long-term support to public as well as private institutions as they tackle challenges and transform the way healthcare is provided. Alberto De Negri, partner of the healthcare practice, discusses his perspective about the Italian healthcare system and the challenges it is currently facing. What have…

Pharma The GM of France for Bristol-Myers Squibb (BMS) discusses becoming a “diversified biopharma company”, their commitment to remaining a model of excellence for other affiliates, and his personal philosophy of leadership, moulded by two decades of international experience. You started off your term with a restructuring plan for the French…

Pharma The CEO of CzechInvest elaborates on the significance of the healthcare and life science industry for the Czech Republic’s transition into an industry 4.0. Furthermore, he reviews what the Czech Republic has to offer for foreign investors over its regional neighbors. Before assuming the position of CEO at CzechInvest you…

Pharma The recently appointed CEO of Servier Hungary, Dr. Jan Frederic Kesselhut highlights his initial perceptions of the Hungarian pharmaceutical market and depicts the significant role that the Servier Research Institute of Medicinal Chemistry (SRIMC) in Hungary plays in the group’s overall R&D activities. He also elaborates on the crucial importance…

Pharma The managing director of Wörwag Pharma Hungary, Dr. Éva Kádár depicts the company’s impressive evolution, highlighting the expansive network of neuropathy centers that they’ve helped establish all over Hungary and the extent of their efforts in creating more awareness for this disorder. As an introduction for our readers, Éva, can…

Pharma Angelini CEO Gianluigi Frozzi speaks about the company’s diverse portfolio of products, the “Made in Italy” brand, and the company’s continual global growth anchored strongly in innovation. Can you please give our readers an overview of Angelini’s operations, both globally and locally? First, I want to explain to our audience that Angelini…

Pharma The country manager for CSL Behring Czech Republic reviews his tremendous success in the country, averaging 50 percent annual growth since 2011. Furthermore, he explains why the current reimbursement system is beneficial for them although it results in high price pressure for innovative pharmaceutical treatments. The question on everybody’s lips…